Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.69, $0.12 better than the analyst estimate of $1.57. Revenue for the quarter came in at $627.7 million versus the consensus estimate of $630.01 million.

GUIDANCE:

Neurocrine Biosciences sees FY2025 revenue of $2.5-2.6 billion, versus the consensus of $2.35 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.